In several malignancies—including pancreatic ductal adenocarcinoma, melanoma, and skin carcinoma—KSR1 has been identified as an oncogenic facilitator of RAS/MAPK signaling, and its genetic or pharmacological inhibition suppresses tumor growth [79]. Here, KSR1 is linked to neoplasm.